Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

The Roadmap to Treatment: A Stepwise Approach

At a Glance

Familial hypercholesterolemia usually needs lifelong treatment to lower LDL (“bad”) cholesterol. Care often starts with a statin, then adds other medicines if needed; goals depend on age, heart disease, and local guidelines.

Managing Familial Hypercholesterolemia (FH) is a lifelong commitment, but it is one with a clear roadmap. Because FH is caused by a genetic “filter” problem rather than diet alone, the goal of treatment is to manually lower the amount of LDL (bad) cholesterol in your blood to safer levels [1][2].

Doctors often use a “stepwise” approach, starting with the most established treatments and adding more specialized tools if your cholesterol levels do not reach their targets [3][4]. However, this is individualized—patients with HoFH, established heart disease, or extremely high LDL-C may need combination therapy immediately rather than waiting through sequential steps.

Safety First: Never stop or alter your prescribed medication without discussing it with your care team. Statins and other lipid-lowering drugs are usually paused during pregnancy and breastfeeding, so preconception counseling is critical. Report any unexpected muscle pain or weakness to your doctor immediately.

The Step-by-Step Treatment Plan

  1. Step 1: Statins (The Cornerstone): Statins are the first-line treatment for almost everyone with FH [3]. They work by slowing down the liver’s production of cholesterol and help the liver’s remaining “docking stations” (receptors) work more efficiently [5]. Most adults with FH will need a “high-intensity” statin, while dosing and starting age differ for children [6].
  2. Step 2: Ezetimibe: If statins alone aren’t enough, ezetimibe is usually the next addition [3]. While statins target cholesterol production, ezetimibe targets cholesterol absorption in the gut [7]. Together, they provide a “double block” that can significantly drop LDL levels [8].
  3. Step 3: PCSK9 Inhibitors: These are highly effective injectable medications (such as evolocumab or alirocumab) [9]. They work by blocking a protein (PCSK9) that normally destroys the liver’s cholesterol docking stations [10]. By keeping those docking stations active, your liver can pull much more cholesterol out of your blood [9][11]. These can cause injection-site reactions.

Treatment Goals

Treatment goals are personalized based on age, risk factors, and regional guidelines. Doctors often aim for at least a 50% reduction from your starting (untreated) LDL level in addition to absolute targets [6][12]. The following are examples of common targets derived from major guidelines (e.g., US and European guidelines), but these are illustrative and your specific target may vary:

Patient Profile Illustrative LDL-C Target
Children (HeFH) Typically <130 mg/dL (or >50% reduction) [13][14]
Children (HoFH) <115 mg/dL [12]
Adults (No Heart Disease) <100 mg/dL (some international guidelines target <70 mg/dL) [6][13]
Adults (With Heart Disease) <55 mg/dL to <70 mg/dL (depending on guidelines) [12][6]

Specialized and Emerging Options

For those who cannot tolerate standard medications or need additional lowering, other options are available (largely for adults, depending on local approvals):

  • Bempedoic Acid: A daily pill for adults that blocks cholesterol production. It can be used by those with statin intolerance but carries a risk of increasing uric acid and triggering gout, as well as possible tendon problems [7][15].
  • Inclisiran: An injection for adults administered initially, again at 3 months, and then every 6 months [16][17].
  • Evinacumab: A specialized infusion for HoFH that works independently of the LDL receptor [18][19].
  • Lipoprotein Apheresis: A physical filtering of blood reserved for severe HoFH or refractory cases [14][20].

Treatment is Lifelong

It is important to remember that FH is a “root cause” condition. While heart-healthy eating and exercise are vital for overall health and risk reduction, they are support players to the medication [21]. The genetic mutation is always present, meaning treatment must be continued consistently to keep your heart protected throughout your life [2].

Common questions in this guide

What medicine is usually started first for familial hypercholesterolemia?
A statin is the usual first-line medicine for most people with familial hypercholesterolemia because it lowers the liver’s cholesterol production and helps the liver remove LDL cholesterol. Adults often need a high-intensity statin, while the starting age and dose for children are individualized.
What is added when a statin does not lower LDL cholesterol enough?
Ezetimibe is often added because it reduces cholesterol absorption in the gut, complementing a statin’s effect. If LDL cholesterol remains above target, a clinician may consider a PCSK9 inhibitor or another therapy; some people need combination treatment from the outset.
What LDL cholesterol target should a person with FH have?
The target depends on age, untreated LDL cholesterol, heart disease, other risk factors, and the guideline used. Clinicians often aim for at least a 50% reduction, with illustrative targets such as below 100 mg/dL for adults without heart disease and below 55 to 70 mg/dL for adults with heart disease. Children’s targets depend on age and whether they have HeFH or HoFH.
Does treatment for familial hypercholesterolemia need to continue for life?
Usually, yes. The genetic cause remains present, so medication must be continued consistently to keep LDL cholesterol lower and protect the heart; healthy eating and exercise support treatment but do not replace it.
Which injectable treatments can be used for familial hypercholesterolemia?
PCSK9 inhibitors such as evolocumab and alirocumab are injectable medicines that help the liver remove more LDL cholesterol. Inclisiran is given initially, again at 3 months, and then every 6 months for adults, while evinacumab is an infusion used for some people with HoFH.
What should I do if an FH medicine causes side effects?
Contact your care team about unexpected muscle pain or weakness rather than stopping the medicine on your own. If standard medicines are not tolerated, options such as bempedoic acid, inclisiran, or injectable therapies may be considered based on age, diagnosis, and local approval.
Can I take FH medicines during pregnancy or breastfeeding?
Statins and other lipid-lowering medicines are usually paused during pregnancy and breastfeeding, so anyone planning pregnancy should discuss timing and alternatives with their care team in advance. Do not stop or change a prescribed medicine without individualized medical guidance.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my (or my child's) current LDL-C, what is our target number, and how much of a percentage reduction are we aiming for?
  2. 2.If we don't reach our target with the first medication, what is the next specific step in our treatment plan?
  3. 3.Are there any lifestyle or dietary changes that are particularly important for my specific genetic type of FH?
  4. 4.How often will we need blood tests to monitor my (or my child's) liver enzymes and cholesterol levels?
  5. 5.At what age or LDL-C level would you consider adding an injectable medication like a PCSK9 inhibitor to the plan?
  6. 6.Is the 'stepwise' approach standard for everyone, or should we be more aggressive earlier because of our family history?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Molecular basis of familial hypercholesterolemia.

    Bruikman CS, Hovingh GK, Kastelein JJP

    Current opinion in cardiology 2017; (32(3)):262-266 doi:10.1097/HCO.0000000000000385.

    PMID: 28169949
  2. 2

    Familial hypercholesterolemia in children and the importance of early treatment.

    van den Bosch SE, Hutten BA, Corpeleijn WE, Kusters DM

    Current opinion in lipidology 2024; (35(3)):126-132 doi:10.1097/MOL.0000000000000926.

    PMID: 38363694
  3. 3

    Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

    Patel J, Shah S, Reddy A, et al.

    Journal of clinical medicine research 2026; (18(3)):121-141 doi:10.14740/jocmr6523.

    PMID: 41953595
  4. 4

    Recent advances in the management and implementation of care for familial hypercholesterolaemia.

    Lan NSR, Bajaj A, Watts GF, Cuchel M

    Pharmacological research 2023; (194()):106857 doi:10.1016/j.phrs.2023.106857.

    PMID: 37460004
  5. 5

    Structural dynamics of LDL receptor interactions with E498A and R499G variants of PCSK9.

    Azhar NAA, Chua YA, Nawawi H, Jusoh SA

    Journal of molecular modeling 2025; (31(6)):161 doi:10.1007/s00894-025-06380-1.

    PMID: 40388017
  6. 6

    Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.

    Albosta MS, Grant JK, Taub P, et al.

    Vascular health and risk management 2023; (19()):421-431 doi:10.2147/VHRM.S338424.

    PMID: 37434791
  7. 7

    Role of Bempedoic Acid in Clinical Practice.

    Ballantyne CM, Bays H, Catapano AL, et al.

    Cardiovascular drugs and therapy 2021; (35(4)):853-864 doi:10.1007/s10557-021-07147-5.

    PMID: 33818688
  8. 8

    The German CaRe high registry for familial hypercholesterolemia - Sex differences, treatment strategies, and target value attainment.

    März W, Schmidt N, An Haack I, et al.

    Atherosclerosis plus 2023; (53()):6-15 doi:10.1016/j.athplu.2023.06.001.

    PMID: 37434912
  9. 9

    Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.

    Tomlinson B, Patil NG, Fok M, Lam CWK

    Endocrinology and metabolism (Seoul, Korea) 2021; (36(2)):279-295 doi:10.3803/EnM.2021.964.

    PMID: 33866776
  10. 10

    PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.

    Grejtakova D, Boronova I, Bernasovska J, Bellosta S

    Cardiovascular drugs and therapy 2025; (39(6)):1439-1451 doi:10.1007/s10557-024-07599-5.

    PMID: 38907775
  11. 11

    Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.

    Agabiti Rosei E, Salvetti M

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2016; (23(3)):217-30 doi:10.1007/s40292-016-0155-2.

    PMID: 27567901
  12. 12

    Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over 10 years of efficacy and safety data.

    Arca M, D'Erasmo L, Cuchel M, et al.

    Journal of clinical lipidology 2025; (19(4)):775-789 doi:10.1016/j.jacl.2025.03.015.

    PMID: 40494715
  13. 13

    Familial hypercholesterolemia treatments: Guidelines and new therapies.

    Raal FJ, Hovingh GK, Catapano AL

    Atherosclerosis 2018; (277()):483-492 doi:10.1016/j.atherosclerosis.2018.06.859.

    PMID: 30270089
  14. 14

    Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022.

    Harada-Shiba M, Ohtake A, Sugiyama D, et al.

    Journal of atherosclerosis and thrombosis 2023; (30(5)):531-557 doi:10.5551/jat.CR006.

    PMID: 36682777
  15. 15

    Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.

    Rubino J, MacDougall DE, Sterling LR, et al.

    Journal of clinical lipidology 2021; (15(4)):593-601 doi:10.1016/j.jacl.2021.05.002.

    PMID: 34172394
  16. 16

    Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).

    Sinning D, Landmesser U

    Current cardiology reports 2020; (22(12)):176 doi:10.1007/s11886-020-01427-6.

    PMID: 33089390
  17. 17

    Treatment of heterozygous familial hypercholesterolemia: what does the future hold?

    Polychronopoulos G, Tziomalos K

    Expert review of clinical pharmacology 2020; (13(11)):1229-1234 doi:10.1080/17512433.2020.1839417.

    PMID: 33070644
  18. 18

    Evinacumab for treatment of familial hypercholesterolemia.

    Warden BA, Duell PB

    Expert review of cardiovascular therapy 2021; (19(8)):739-751 doi:10.1080/14779072.2021.1955349.

    PMID: 34253139
  19. 19

    The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.

    Raal FJ, Rosenson RS, Reeskamp LF, et al.

    JACC. Advances 2023; (2(9)):100648 doi:10.1016/j.jacadv.2023.100648.

    PMID: 38938723
  20. 20

    Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.

    Klaus G, Taylan C, Büscher R, et al.

    Pediatric nephrology (Berlin, Germany) 2018; (33(7)):1199-1208 doi:10.1007/s00467-018-3906-6.

    PMID: 29502162
  21. 21

    Association of the Interaction Between Familial Hypercholesterolemia Variants and Adherence to a Healthy Lifestyle With Risk of Coronary Artery Disease.

    Fahed AC, Wang M, Patel AP, et al.

    JAMA network open 2022; (5(3)):e222687 doi:10.1001/jamanetworkopen.2022.2687.

    PMID: 35294538

This page explains stepwise treatment for familial hypercholesterolemia for informational purposes only and does not constitute medical advice. Your clinician should set medication choices, LDL-C targets, and pregnancy-related plans for you or your child.

Get notified when new evidence is published on Familial hypercholesterolemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.